Comparison of Dabigatran Etexilate and Warfarin in Anticoagulation in Patients with Nonvalvular Atrial Fibrillation
Objective:To analyze the effect of Dabigatran Etexilate and Warfarin in anticoagulation in patients with nonvalvular atrial fibrillation(NVAF).Method:A total of 102 NVAF patients diagnosed and treated in Baiyun Hospital,Guizhou Medical University from June 2020 to June 2023 were divided into two groups by random drawing method,with 51 cases in each group.The control group received anticoagulant therapy with Warfarin and the observation group received anticoagulant therapy with Dabigatran Etexilate.The clinical effects of the two anticoagulant treatments were compared.Result:There were no significant differences in the incidence of embolism or thrombosis,ischemic stroke,minor bleeding,major bleeding or hemorrhagic stroke and death between the two groups(P>0.05),and the incidence of slight bleeding between the two groups was statistically significant(P<0.05).Before treatment,there were no significant differences in the level of coagulation indexes between the two groups(P>0.05);after treatment,the international normalized ratio(INR)level in the observation group was(1.15±0.66),which was lower than(1.68±0.71)in the control group,and the difference was statistically significant(P<0.05).The level of activated partial thromboplastin time(APTT)in the observation group was higher and the difference was statistically significant(P<0.05).There were no significant differences in the other coagulation function indexes between the two groups(P>0.05).Before treatment and after 3 months of treatment,there were no significant differences in creatinine and alanine aminotransferase levels between the two groups(P>0.05).Conclusion:Compared with Warfarin,Dabigatran Etexilate can reduce the risk of bleeding and improve the coagulation function of patients with NVAF in anticoagulation therapy,the effect is ideal.
万方数据
维普
